article thumbnail

Accenture Invests in QuantHealth to Accelerate Use of AI-Powered Clinical Trial Simulations to Drive Cost-Effective Drug Development

Healthcare IT Today

Accenture announced it has made a strategic investment, through Accenture Ventures , in QuantHealth , an AI-powered clinical trial design company that simulates clinical trials in the cloud, allowing pharmaceutical and biotech companies to more quickly and cost-effectively develop treatments for patients. Petra Jantzer, Ph.D.,

article thumbnail

How AI is Shaping Drug Discovery at AION Labs

Healthcare IT Today

In our interview, Gil emphasizes the critical role of AI in expediting the discovery of new drugs, citing the lengthy and costly nature of traditional drug development processes. However, with AI-driven approaches, Aion Labs is paving the way for a paradigm shift in drug discovery.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Patients and Industry: Starting Our New Life Together in 2023

Society for Participatory Medicine

The FDA issued a series of four patient-focused drug development (PFDD) guidance documents which outline how patient co-design needs to successfully happen. After all of this time and energy expended, it’s only right that patients would be witness to accountability of pharma/biotech to incorporate our collective voice.

BioTech 112
article thumbnail

Let’s Save the Date and Make Patient Engagement Official in 2022

Society for Participatory Medicine

Healthcare stakeholders such as health systems, pharmaceutical companies, biotech and life sciences firms, and insurance companies serve patients as end users. The same definition of patient engagement applies to industry, except that the interventions lead to more human centered design and value-based care.

BioTech 97
article thumbnail

Pharma IT and AI – 2024 Health IT Predictions

Healthcare IT Today

Now, they have new tools such as artificial intelligence (AI) and machine learning (ML) that they can leverage to automatically scour medical literature for information to assist signal evaluation and medical review, or real-world-evidence insights that can lead to drug-safety improvements. Dave Latshaw, CEO at BioPhy 1.

article thumbnail

PhaseV Raises $15 Million to Push the Boundaries of ML for Clinical Trial Optimization

Healthcare IT Today

This ML-driven adaptive process can significantly accelerate the clinical drug development process and increase certainty along the way, resulting in more efficient, targeted, and ultimately more successful clinical trials. bringing new needed treatments to patients.”

article thumbnail

Digital Health Technologies in Clinical Trials

Digital Health Global

Furthermore, by fostering connectivity and automating tasks, DHTs reduce administrative burdens, accelerate recruitment, and improve overall trial transparency, ultimately contributing to faster and more reliable drug development.